pharma-middle-east-2018-scientifictracks

7 / 17

Page 28
Notes:
conferenceseries.com
Volume 5 Journal of Pharmaceutical Care & Health Systems Pharma Middle East 2018
November 05-07, 2018
November 05-07, 2018 Abu Dhabi, UAE
18th Annual
Pharma Middle East Congress
Hyaluronic acid decorated tacrolimus-loaded nanoparticles: Efficient approach to maximize dermal
targeting and anti-dermatitis efficacy
Zahid Hussain
Universiti Teknologi MARA System, Malaysia
Atopic Dermatitis (AD) is a chronically relapsing eczematous skin disease characterized by frequent episodes of rashes,
severe flares and inflammation. Till date, there is no absolute therapy for the treatment of AD. However, Topical
Corticosteroids (TCs) are the majorly prescribed class of drugs for the management of AD. However due to numerous local
and systemic adverse effects associated with the use of TCs, Topical Calcineurin Inhibitors (TCIs) have alternatively been
well prescribed agents. Though, topical route is most preferable however, a limited penetration of therapeutics across the
Stratum Corneum (SC) is one of the major challenges to topical formulations. Owing to excellent biomedical achievements
of nanomedicines in the last few decades, nano-delivery systems have gained remarkable recognition for targeted delivery
of therapeutic payload, reduced off-target effects and improved biopharmaceutical profiles of drugs. Therefore, we aimed
to fabricate polymeric Nanoparticles (NPs) to deliver Tacrolimus (TCs) to deeper layers of the skin in order to alleviate its
systemic toxicity and improved therapeutic efficacy for treatment of AD. To further optimize the targeting efficiency, TCS-
loaded NPs were coated with Hyaluronic Acid (HA). HA plays multifaceted role in regulating the various biological processes
and maintaining homeostasis into the body. Plenteous researches have evidenced the biomedical implications of HA in the skin
repair, wound healing, tissue regeneration, anti-inflammatory, and immunomodulation. Following the various physicochemical
optimizations, the prepared HA-TCS-CS-NPs were tested for in vitro drug release kinetics, drug permeation across the stratum
corneum, percentage of drug retained in the epidermis, dermis and anti-AD efficacy. Results revealed that HA-TCS-CS-NPs
exhibit sustained release profile, promising drug permeation ability, improved skin retention and pronounced anti-AD efficacy.
Conclusively, we anticipated that HA-based modification of TCS-CS-NPs could be a promising therapeutic approach for
rationalized management of AD, particularly in children as well as in adults having steroid phobia.
Biography
Zahid Hussain is currently working as an Assistant Professor in the Department of Pharmaceutics, Faculty of Pharmacy, Universiti Teknologi MARA, Malaysia. He
is also the Executive Head of Quality Control Department of Good Manufacturing Practices Unit at Universiti Teknologi MARA, Malaysia. He has authored more
than 50 peer-reviewed research/review articles with high impact factor, well-ranked international journals and 3 book chapters. He is recipient of several prestigious
honors and awards. He is the Editorial Board Member for 3 international journals and is also the Official Reviewer of more than 30 well-reputed peer-reviewed
international journals. His research interests include fabrication, characterization and formulation of nanotechnology-based topical, percutaneous and transdermal
drug delivery systems for the efficient management of skin inflammatory disorders including psoriasis, atopic dermatitis and acute-to-chronic wound.
Zahid Hussain, J Pharma Care Health Sys 2018, Volume 5
DOI: 10.4172/2376-0419-C4-035